Release Date: November 08, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Docebo Inc (DCBO, Financial) reported a strong quarter with consistent execution and profitability, despite a challenging macro environment.
- The company has successfully expanded its partnerships, notably with Accenture and Deloitte, enhancing its market presence and sales execution.
- Docebo Inc (DCBO) has launched a new pricing strategy that aligns value with customer outcomes, which has been well-received and is expected to drive higher average contract values.
- The company is seeing strong growth in its enterprise segment, with a focus on external use cases and customer experience learning, which now constitutes a significant portion of its pipeline.
- Docebo Inc (DCBO) is making strategic investments in its product offerings, including the upcoming launch of AI Authoring, which has garnered significant interest and is expected to streamline content production.
Negative Points
- The enterprise segment growth rate has decelerated to 25%, partly due to seasonal factors and tough comparisons from the previous year.
- The deal cycle in the enterprise market remains elongated, which could impact the timing of revenue recognition.
- The company is still awaiting FedRAMP certification, which is crucial for participating in large federal opportunities, and the timeline for this remains uncertain.
- There is increased scrutiny and elongated sales cycles in the current economic environment, which could affect future growth rates.
- Free cash flow was lower than expected due to working capital changes, including the timing of bonus payments, which may indicate potential cash flow volatility.
Q & A Highlights
Q: Can you discuss the company's performance in the current challenging macro environment and the mix between direct sales and partner relationships?
A: Alessio Artuffo, President, COO, and Interim CEO, highlighted the company's strong execution in a stable yet challenging market. He emphasized Docebo's unique ability to serve large enterprises' needs for both employee and customer experiences. The company balances investments in direct sales and partner relationships, with system integrators playing a key role. Success with partners like Accenture in Europe underscores the effectiveness of their strategy.
Q: Could you provide an update on the progress with FedRAMP certification and any potential impacts from a new administration?
A: Alessio Artuffo explained that Docebo is audit-ready for FedRAMP and actively working to finalize the ATO sponsorship. While the timeline is uncertain, they remain cautiously optimistic. He noted that government agencies may need to do more with less, and Docebo's platform supports upskilling and reskilling, providing an edge in efficiency.
Q: How is the new pricing strategy progressing, and what feedback have you received?
A: Sukaran Mehta, CFO, stated that the new core bundle pricing launched in April has driven higher value conversations with customers. The strategy aligns value with customer education use cases and has been well-received, reflected in strong ACV growth. The new pricing is expected to streamline renewals and support expansion in 2025.
Q: Can you update us on the growth by customer cohort, particularly the enterprise segment?
A: Sukaran Mehta reported that the enterprise segment grew by 25% this quarter, while SMB growth remained in single digits. The focus remains on the higher end of the market, with potential for SMB participation if market conditions stabilize.
Q: What is the status of the OEM strategy and potential headwinds from prior changes?
A: Alessio Artuffo mentioned that the partner strategy, including OEM channels, remains strong. They have brought in new leadership to enhance strategic partnerships. The focus is on supporting large enterprises and leveraging system integrators like Accenture and Deloitte for growth.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.